These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 24187330)

  • 1. Cost-effectiveness analysis of cochlear dose reduction by proton beam therapy for medulloblastoma in childhood.
    Hirano E; Fuji H; Onoe T; Kumar V; Shirato H; Kawabuchi K
    J Radiat Res; 2014 Mar; 55(2):320-7. PubMed ID: 24187330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost effectiveness of proton therapy compared with photon therapy in the management of pediatric medulloblastoma.
    Mailhot Vega RB; Kim J; Bussière M; Hattangadi J; Hollander A; Michalski J; Tarbell NJ; Yock T; MacDonald SM
    Cancer; 2013 Dec; 119(24):4299-307. PubMed ID: 24105630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Effectiveness of Proton Versus Photon Therapy in Pediatric Medulloblastoma Treatment: A Patient Volume-Based Analysis.
    Fernandes RRA; Vianna CMM; Guerra RL; Cancela MC; Almeida LM; Pereira AJDC; Viégas CMP; Ferman SE; Corrêa F
    Value Health Reg Issues; 2019 Dec; 20():122-128. PubMed ID: 31319299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ototoxicity and cochlear sparing in children with medulloblastoma: Proton vs. photon radiotherapy.
    Paulino AC; Mahajan A; Ye R; Grosshans DR; Fatih Okcu M; Su J; McAleer MF; McGovern S; Mangona VA; Chintagumpala M
    Radiother Oncol; 2018 Jul; 128(1):128-132. PubMed ID: 29373195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of proton radiation in the treatment of childhood medulloblastoma.
    Lundkvist J; Ekman M; Ericsson SR; Jönsson B; Glimelius B
    Cancer; 2005 Feb; 103(4):793-801. PubMed ID: 15637691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of proton beam therapy for treatment decision making in paranasal sinus and nasal cavity cancers in China.
    Li G; Qiu B; Huang YX; Doyen J; Bondiau PY; Benezery K; Xia YF; Qian CN
    BMC Cancer; 2020 Jun; 20(1):599. PubMed ID: 32590957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical Evaluation of Proton Therapy - How much benefit can be considered a benefit?].
    Combs SE
    Strahlenther Onkol; 2016 Jul; 192(7):498-9. PubMed ID: 27272659
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment planning with protons for pediatric retinoblastoma, medulloblastoma, and pelvic sarcoma: how do protons compare with other conformal techniques?
    Lee CT; Bilton SD; Famiglietti RM; Riley BA; Mahajan A; Chang EL; Maor MH; Woo SY; Cox JD; Smith AR
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):362-72. PubMed ID: 16168831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term toxic effects of proton radiotherapy for paediatric medulloblastoma: a phase 2 single-arm study.
    Yock TI; Yeap BY; Ebb DH; Weyman E; Eaton BR; Sherry NA; Jones RM; MacDonald SM; Pulsifer MB; Lavally B; Abrams AN; Huang MS; Marcus KJ; Tarbell NJ
    Lancet Oncol; 2016 Mar; 17(3):287-298. PubMed ID: 26830377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimated clinical benefit of protecting neurogenesis in the developing brain during radiation therapy for pediatric medulloblastoma.
    Blomstrand M; Brodin NP; Munck Af Rosenschöld P; Vogelius IR; Sánchez Merino G; Kiil-Berthlesen A; Blomgren K; Lannering B; Bentzen SM; Björk-Eriksson T
    Neuro Oncol; 2012 Jul; 14(7):882-9. PubMed ID: 22611031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cochlear dose and the age at radiotherapy predict severe hearing loss after passive scattering proton therapy and cisplatin in children with medulloblastoma.
    Abu-Arja MH; Brown AL; Su JM; Okcu MF; Lindsay HB; McGovern SL; McAleer MF; Grosshans DR; Chintagumpala MM; Paulino AC
    Neuro Oncol; 2024 Oct; 26(10):1912-1920. PubMed ID: 38916058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating the Cost-Effectiveness of Hydrogel Rectal Spacer in Prostate Cancer Radiation Therapy.
    Levy JF; Khairnar R; Louie AV; Showalter TN; Mullins CD; Mishra MV
    Pract Radiat Oncol; 2019 Mar; 9(2):e172-e179. PubMed ID: 30342180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimizing the radiation therapy dose prescription for pediatric medulloblastoma: minimizing the life years lost attributable to failure to control the disease and late complication risk.
    Brodin NP; Vogelius IR; Björk-Eriksson T; Munck Af Rosenschöld P; Maraldo MV; Aznar MC; Specht L; Bentzen SM
    Acta Oncol; 2014 Apr; 53(4):462-70. PubMed ID: 24274390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NHS will pay for boy's proton beam therapy in Prague.
    Dyer C
    BMJ; 2014 Sep; 349():g5944. PubMed ID: 25270423
    [No Abstract]   [Full Text] [Related]  

  • 15. Hippocampal sparing radiotherapy for pediatric medulloblastoma: impact of treatment margins and treatment technique.
    Brodin NP; Munck af Rosenschöld P; Blomstrand M; Kiil-Berthlesen A; Hollensen C; Vogelius IR; Lannering B; Bentzen SM; Björk-Eriksson T
    Neuro Oncol; 2014 Apr; 16(4):594-602. PubMed ID: 24327585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proton radiation therapy for pediatric medulloblastoma and supratentorial primitive neuroectodermal tumors: outcomes for very young children treated with upfront chemotherapy.
    Jimenez RB; Sethi R; Depauw N; Pulsifer MB; Adams J; McBride SM; Ebb D; Fullerton BC; Tarbell NJ; Yock TI; Macdonald SM
    Int J Radiat Oncol Biol Phys; 2013 Sep; 87(1):120-6. PubMed ID: 23790826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimizing oropharyngeal cancer management by using proton beam therapy: trends of cost-effectiveness.
    Li G; Xia YF; Huang YX; Okat D; Qiu B; Doyen J; Bondiau PY; Benezery K; Gao J; Qian CN
    BMC Cancer; 2021 Aug; 21(1):944. PubMed ID: 34419008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-Effectiveness Analysis of Intensity Modulated Radiation Therapy Versus 3-Dimensional Conformal Radiation Therapy for Preoperative Treatment of Extremity Soft Tissue Sarcomas.
    Richard P; Phillips M; Smith W; Davidson D; Kim E; Kane G
    Int J Radiat Oncol Biol Phys; 2016 Jul; 95(3):999-1008. PubMed ID: 27130792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence of CNS Injury for a Cohort of 111 Patients Treated With Proton Therapy for Medulloblastoma: LET and RBE Associations for Areas of Injury.
    Giantsoudi D; Sethi RV; Yeap BY; Eaton BR; Ebb DH; Caruso PA; Rapalino O; Chen YE; Adams JA; Yock TI; Tarbell NJ; Paganetti H; MacDonald SM
    Int J Radiat Oncol Biol Phys; 2016 May; 95(1):287-296. PubMed ID: 26691786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis using lifetime attributable risk of proton beam therapy for pediatric medulloblastoma in Japan.
    Yoshimura T; Tamori H; Morii Y; Hashimoto T; Shimizu S; Ogasawara K
    J Radiat Res; 2021 Sep; ():. PubMed ID: 34590123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.